 Efineptakin alfa in combination with pembrolizumab induced 27.8 ORR in metastatic TNBC patients in a phase 1b2 trial in South Korea Efineptakin alfa in patients with GBM showed a 83.3 survival ratio over one year in a phase 1 trial in the U.S. SHANGHAI and GAITHERSBURG, Md., July 28, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that an IND application for the initiation of a phase 2 clinical trial of efineptakin alfa also known as TJ107GX-I7NT-I7 in combination with anti-PD-1 antibody in patients with advanced solid tumors, including triple-negative breast cancer TNBC and head and neck cancers HNC, has been accepted by the Center for Drug Evaluation CDE of the China National Medical Products Administration NMPA. 